vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
AMBARELLA INC is the larger business by last-quarter revenue ($108.5M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, AMBARELLA INC posted the faster year-over-year revenue change (31.2% vs 17.7%). AMBARELLA INC produced more free cash flow last quarter ($31.4M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 45.0%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
AMBA vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $86.8M |
| Net Profit | $-15.1M | — |
| Gross Margin | 59.6% | 67.4% |
| Operating Margin | -15.0% | -84.7% |
| Net Margin | -13.9% | — |
| Revenue YoY | 31.2% | 17.7% |
| Net Profit YoY | 37.2% | — |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | $86.8M | ||
| Q3 25 | $95.5M | $67.5M | ||
| Q2 25 | $85.9M | $60.0M | ||
| Q1 25 | $84.0M | $49.3M | ||
| Q4 24 | $82.7M | $73.7M | ||
| Q3 24 | $63.7M | $58.6M | ||
| Q2 24 | $54.5M | $31.1M | ||
| Q1 24 | $51.6M | $715.0K |
| Q4 25 | $-15.1M | — | ||
| Q3 25 | $-20.0M | $-91.3M | ||
| Q2 25 | $-24.3M | $-111.7M | ||
| Q1 25 | $-20.2M | $-116.2M | ||
| Q4 24 | $-24.1M | — | ||
| Q3 24 | $-34.9M | $-83.5M | ||
| Q2 24 | $-37.9M | $-97.1M | ||
| Q1 24 | $-60.6M | $-113.0M |
| Q4 25 | 59.6% | 67.4% | ||
| Q3 25 | 58.9% | 43.0% | ||
| Q2 25 | 60.0% | 5.5% | ||
| Q1 25 | 60.0% | -0.8% | ||
| Q4 24 | 60.6% | 68.7% | ||
| Q3 24 | 60.8% | 46.2% | ||
| Q2 24 | 60.9% | -0.8% | ||
| Q1 24 | 59.8% | — |
| Q4 25 | -15.0% | -84.7% | ||
| Q3 25 | -23.0% | -140.7% | ||
| Q2 25 | -30.1% | -189.8% | ||
| Q1 25 | -30.2% | -245.8% | ||
| Q4 24 | -30.9% | -117.5% | ||
| Q3 24 | -56.9% | -152.1% | ||
| Q2 24 | -72.4% | -327.6% | ||
| Q1 24 | -80.8% | -16464.6% |
| Q4 25 | -13.9% | — | ||
| Q3 25 | -20.9% | -135.3% | ||
| Q2 25 | -28.3% | -186.2% | ||
| Q1 25 | -24.1% | -235.5% | ||
| Q4 24 | -29.1% | — | ||
| Q3 24 | -54.8% | -142.7% | ||
| Q2 24 | -69.6% | -312.2% | ||
| Q1 24 | -117.4% | -15800.8% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.47 | — | ||
| Q2 25 | $-0.58 | $-0.33 | ||
| Q1 25 | $-0.48 | $-0.36 | ||
| Q4 24 | $-0.58 | $-0.24 | ||
| Q3 24 | $-0.85 | $-0.28 | ||
| Q2 24 | $-0.93 | $-0.34 | ||
| Q1 24 | $-1.51 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $590.1M | $698.6M |
| Total Assets | $751.9M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | $297.0M | ||
| Q3 25 | $142.7M | $300.8M | ||
| Q2 25 | $141.3M | $301.2M | ||
| Q1 25 | $144.6M | $359.7M | ||
| Q4 24 | $127.1M | $323.8M | ||
| Q3 24 | $153.9M | $397.5M | ||
| Q2 24 | $131.8M | $412.5M | ||
| Q1 24 | $144.9M | $356.2M |
| Q4 25 | $590.1M | $698.6M | ||
| Q3 25 | $576.5M | $702.3M | ||
| Q2 25 | $572.7M | $698.5M | ||
| Q1 25 | $561.4M | $767.9M | ||
| Q4 24 | $554.3M | $710.4M | ||
| Q3 24 | $547.6M | $773.5M | ||
| Q2 24 | $555.4M | $768.5M | ||
| Q1 24 | $559.9M | $680.0M |
| Q4 25 | $751.9M | $913.2M | ||
| Q3 25 | $706.4M | $904.9M | ||
| Q2 25 | $701.9M | $907.4M | ||
| Q1 25 | $689.0M | $966.7M | ||
| Q4 24 | $670.8M | $910.4M | ||
| Q3 24 | $650.3M | $991.1M | ||
| Q2 24 | $638.7M | $964.3M | ||
| Q1 24 | $657.7M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $-52.6M |
| Free Cash FlowOCF − Capex | $31.4M | $-61.9M |
| FCF MarginFCF / Revenue | 29.0% | -71.3% |
| Capex IntensityCapex / Revenue | 2.7% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | $-52.6M | ||
| Q3 25 | $5.5M | $-78.7M | ||
| Q2 25 | $14.8M | $-67.4M | ||
| Q1 25 | $25.4M | $-103.7M | ||
| Q4 24 | $6.6M | $-73.3M | ||
| Q3 24 | $16.7M | $-59.0M | ||
| Q2 24 | $-15.0M | $-98.4M | ||
| Q1 24 | $-4.0M | $-122.3M |
| Q4 25 | $31.4M | $-61.9M | ||
| Q3 25 | $1.4M | $-89.5M | ||
| Q2 25 | $10.2M | $-74.9M | ||
| Q1 25 | $21.2M | $-109.9M | ||
| Q4 24 | $4.1M | $-77.5M | ||
| Q3 24 | $14.2M | $-61.3M | ||
| Q2 24 | $-16.1M | $-98.9M | ||
| Q1 24 | $-6.0M | $-126.5M |
| Q4 25 | 29.0% | -71.3% | ||
| Q3 25 | 1.4% | -132.7% | ||
| Q2 25 | 11.9% | -124.9% | ||
| Q1 25 | 25.3% | -222.8% | ||
| Q4 24 | 5.0% | -105.1% | ||
| Q3 24 | 22.2% | -104.6% | ||
| Q2 24 | -29.5% | -317.9% | ||
| Q1 24 | -11.6% | -17685.3% |
| Q4 25 | 2.7% | 10.7% | ||
| Q3 25 | 4.3% | 16.1% | ||
| Q2 25 | 5.3% | 12.4% | ||
| Q1 25 | 5.0% | 12.6% | ||
| Q4 24 | 3.0% | 5.7% | ||
| Q3 24 | 4.0% | 3.9% | ||
| Q2 24 | 2.1% | 1.4% | ||
| Q1 24 | 3.7% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
